Shukra Pharmaceuticals Ltd
SHUKRAPHARShukra Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +127.3% in a year against a +90.4% price move.
The sharpest disagreement: profits are rising, but only 14% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (3 weeks in) while the P/E sits at the 72nd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +1,200.0% year on year, and 14% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Shukra Pharmaceuticals Ltd trades at ₹53.9, in a confirmed uptrend and 3 weeks into that stage. That is +49.0% against its own 200-day average. It sits at 89% of a 52-week range of ₹13 to ₹59. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.
Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹53.9 it trades +49.0% versus its 200-day average and sits at 89% of its 52-week range (₹13–₹59).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +20,646% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Shukra Pharmaceuticals Ltd trades at 70.0× P/E, at the pricey end of its own range (72nd percentile). Its long-run median P/E is 60.1×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 70.0× is at the pricey end of its own range (72nd percentile), against a long-run median of 60.1× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +127.3% against a +90.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 10y, of the +69.2%/yr price move, ~+54.4%/yr came from earnings growth and ~+14.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Shukra Pharmaceuticals Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −50.0% at the trough to +230.0% off a 5-quarter-old trough, ROCE lifting at 37.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +72.7% | −1.1% | +39.0% | +27.6% |
| Profit | +120.0% | +76.5% | — | — |
| EPS | +127.3% | +71.0% | — | — |
| Share price | +90.4% | +135.3% | +164.1% | +69.2% |
4-Factor Sector Score
75.5/100 — rank 1 of 10 in Pharma - Others · 74% evidence confidence
Shukra Pharmaceuticals Ltd scores 75.5 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 30.5 + 19.1 + 9.3 + 16.6 = 75.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Shukra Pharmaceuticals Ltd reported ₹24.0 Cr of revenue in the Jun 26 quarter, +380.0% year on year. Over 10 years it has compounded at 27.6% a year. The last full year, FY26, came in at ₹57.0 Cr. The last four reported quarters add to ₹75.0 Cr.
FY26 revenue came in at ₹57.0 Cr (+72.7% on the year), capping 10 years at 27.6% compound. The latest quarter (Jun 26) printed ₹24.0 Cr, +380.0% year on year.
Pace check: the last four quarters averaged +145.2% growth against the decade's 27.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +114.3% over the last 4 quarters against +13.7%/yr over the last 8 — accelerating; TTM profit +230.0% vs +35.4%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Shukra Pharmaceuticals Ltd's operating margin is 81.0% in the Jun 26 quarter, +57.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged −10.0% to 51.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 81.0%, +57.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −10.0%–51.0%, and FY26's 51.0% is the top of that band — a record year.
Why the margin moved: operating margin went +56.9 pp year on year while gross margin went +20.8 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Shukra Pharmaceuticals Ltd earned ₹13.0 Cr of net profit in the Jun 26 quarter, +1,200.0% year on year. Full-year FY26 profit was ₹22.0 Cr. That is 54.2% of the quarter's revenue. The same quarter a year earlier earned ₹1.0 Cr. 1 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹13.0 Cr, +1,200.0% year on year. On the full year, FY26 printed ₹22.0 Cr (+120.0%).
Why profit moved: revenue contributed +380.0% and the margin +57.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +431.7% vs revenue +145.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 14% of Shukra Pharmaceuticals Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹4.0 Cr of operating cash against ₹22.0 Cr of profit. After ₹16.0 Cr of capital spending, ₹−12.0 Cr was left as free cash.
FY26: operating cash of ₹4.0 Cr against reported profit of ₹22.0 Cr, leaving free cash of ₹−12.0 Cr after ₹16.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 14% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 14%: the cash cycle stretched 399 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 399 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Shukra Pharmaceuticals Ltd's cash conversion cycle runs 236 days in FY26, up from −163 days in FY21. Capital spending ran ₹20.0 Cr over the last 3 years. At FY26 sales of ₹57.0 Cr each day of that cycle holds about ₹0.2 Cr, so roughly ₹37.0 Cr sits inside the business at any moment.
FY26: debtors at 148 days, inventory at 320 days — roughly 10.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 236 days, looser than FY21's −163.
The full loop: cash goes out to suppliers and production on day 0; stock waits 320 days to sell; customers pay about 148 days after that; and suppliers themselves are paid at 232 days — netting out to the 236-day cycle.
In money terms: at FY26 sales of ₹57.0 Cr, each day of the cycle holds about ₹0.2 Cr — so the 236-day loop keeps roughly ₹37.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹20.0 Cr over the last 3 fiscal years against ₹8.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹12.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Shukra Pharmaceuticals Ltd earns a ROCE of 37% in FY26. That is up from a trough of −6% in FY14. Return on invested capital clears the cost of that capital by +27.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 38.6% net margin on 0.49× asset turns.
FY26 ROCE is 37%, recovered from a FY14 trough of −6% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 38.6% net margin × 0.49× asset turns × 1.30× balance-sheet leverage ≈ 24.6% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 39.3% − 12.0% = a +27.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Shukra Pharmaceuticals Ltd carries ₹5.0 Cr of borrowings against ₹90.0 Cr of equity in FY26, a debt-to-equity of 0.06. Operating profit covers the interest bill 29×. Over 5 years borrowings went from ₹10.0 Cr to ₹5.0 Cr. Capital spending ran ₹20.0 Cr across the last 3 of those years.
FY26: borrowings of ₹5.0 Cr against equity of ₹90.0 Cr — a debt-to-equity of 0.06. Operating profit covers the interest bill 29×. Over 5 years borrowings went from ₹10.0 Cr to ₹5.0 Cr while capital spending ran ₹20.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Shukra Pharmaceuticals Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.0 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +0.2 points over 8 quarters to 51.2%; Domestic institutions: +0.0 points over 8 quarters to 0.1%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Shukra Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Shukra Pharmaceuticals Ltdthis pageSHUKRAPHAR | 75.5/100Favorable setup74% evidence | 30.5/35 Revenue 100% · PAT 100% · OPM change 57 pp 95% evidence | 19.1/25 ROCE 36.9% · OPM 81% 95% evidence | 9.3/20 P/E 70× · PEG — 15% evidence | 16.6/20 RS sector 49.8% · RS bench 40.5% · 1Y 94%9 of 12 weeks ahead 70% evidence | |
| Exact sum: 30.5 + 19.1 + 9.3 + 16.6 = 75.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2JOJO Ltd531910 | 64.9/100Mixed-positive evidence61% evidence | ASLEEP | 26.3/35 Revenue 100% · PAT 100% · OPM change 53.1 pp 71% evidence | 14.2/25 ROCE 17% · OPM 44.7% 76% evidence | 8.9/20 P/E 218× · PEG — 15% evidence | 15.5/20 RS sector 4.3% · RS bench 86.8% · 1Y -6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 26.3 + 14.2 + 8.9 + 15.5 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Syncom Formulations (India) LtdSYNCOMF | 64.2/100Mixed-positive evidence87% evidence | BREAKING OUT | 21.6/35 Revenue 0.4% · PAT 48.3% · OPM change 7 pp 95% evidence | 17.8/25 ROCE 26.8% · OPM 21% 95% evidence | 9.4/20 P/E 21.4× · PEG — 50% evidence | 15.4/20 RS sector -1% · RS bench 35.2% · 1Y 13.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 17.8 + 9.4 + 15.4 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Remus Pharmaceuticals LtdREMUS | 54.2/100Mixed-positive evidence70% evidence | TURNING | 19.2/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 14.6/25 ROCE 16.8% · OPM 7% 95% evidence | 10.7/20 P/E 28× · PEG — 50% evidence | 9.7/20 RS sector -10.3% · RS bench 22.1% · 1Y 4.7%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 14.6 + 10.7 + 9.7 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Sun Pharma Advanced Research Company LtdSPARC | 52.6/100Mixed-positive evidence81% evidence | FADING | 17.7/35 Revenue 100% · PAT 100% · OPM change 455 pp 74% evidence | 13.0/25 ROCE 164% · OPM -85% 100% evidence | 15.0/20 P/E 4× · PEG — 50% evidence | 6.9/20 RS sector -9% · RS bench 22.2% · 1Y 35.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 13 + 15 + 6.9 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Jenburkt Pharmaceuticals Ltd524731 | 50.7/100Mixed-positive evidence78% evidence | 16.5/35 Revenue 11.8% · PAT 6.1% · OPM change 6 pp 83% evidence | 19.1/25 ROCE 27.2% · OPM 32% 76% evidence | 9.0/20 P/E 13.2× · PEG — 50% evidence | 6.1/20 RS sector -9.9% · RS bench 0.4% · 1Y -3%0 of 1 week ahead to 2026-06-28 100% evidence | |
| Exact sum: 16.5 + 19.1 + 9 + 6.1 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7TTK Healthcare LtdTTKHLTCARE | 43.4/100Mixed-negative evidence81% evidence | BREAKING OUT | 16.8/35 Revenue 8.6% · PAT 17.5% · OPM change 4.8 pp 95% evidence | 7.1/25 ROCE 8% · OPM 6% 95% evidence | 13.0/20 P/E 20.6× · PEG — 50% evidence | 6.5/20 RS sector -20.5% · RS bench 12.9% · 1Y -3.1%10 of 10 weeks ahead 70% evidence |
| Exact sum: 16.8 + 7.1 + 13 + 6.5 = 43.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Unichem Laboratories LtdUNICHEMLAB | 40.9/100Mixed-negative evidence67% evidence | LEADER | 12.8/35 Revenue 7.2% · PAT 100% · OPM change 6.7 pp 71% evidence | 6.9/25 ROCE 4.1% · OPM 11% 76% evidence | 9.6/20 P/E 31.1× · PEG — 15% evidence | 11.6/20 RS sector -7.4% · RS bench 25.8% · 1Y 7.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.9 + 9.6 + 11.6 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Panacea Biotec LtdPANACEABIO | 24.1/100Adverse evidence80% evidence | ASLEEP | 11.7/35 Revenue 10.3% · PAT -80% · OPM change 3.5 pp 100% evidence | 1.6/25 ROCE -2.4% · OPM 2.8% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.8/20 RS sector -26.9% · RS bench -0.4% · 1Y -2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 1.6 + 10 + 0.8 = 24.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Madhuveer Com 18 Network LtdMADHUVEER | 47.8/100Thin evidence · provisional50% evidence | 16.2/35 Revenue 68.7% · PAT 12.8% · OPM change 18.4 pp 53% evidence | 9.3/25 ROCE -1.1% · OPM 69.7% 57% evidence | 8.5/20 P/E 660× · PEG — 15% evidence | 13.8/20 RS sector 14.3% · RS bench 6.3% · 1Y -3.3%12 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.2 + 9.3 + 8.5 + 13.8 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Shukra Pharmaceuticals Ltd's share price today?
Shukra Pharmaceuticals Ltd trades at ₹53.9, +90.4% over the past year. The company is valued at ₹2,378 Cr. The stock sits at 89% of its 52-week range of ₹13–₹59, +49.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 3 weeks in. — as of 11 September 2026.
What were Shukra Pharmaceuticals Ltd's latest quarterly results?
Shukra Pharmaceuticals Ltd reported revenue of ₹24.0 Cr and net profit of ₹13.0 Cr for the Jun 26 quarter. Revenue rose 380.0% and profit rose 1,200.0% year on year. Earnings per share were ₹0.29. The operating margin was 81.0%, 57.0 pp higher than a year earlier. — as of 11 September 2026.
What is Shukra Pharmaceuticals Ltd's revenue?
Shukra Pharmaceuticals Ltd reported revenue of ₹24.0 Cr in the Jun 26 quarter, +380.0% year on year. For the full FY26 fiscal year, revenue was ₹57.0 Cr (+72.7%). Over the last 10 years revenue compounded at 27.6% a year. — as of 11 September 2026.
What is Shukra Pharmaceuticals Ltd's profit?
Shukra Pharmaceuticals Ltd earned ₹13.0 Cr of net profit in the Jun 26 quarter, +1,200.0% year on year. Full-year FY26 profit was ₹22.0 Cr. The operating margin ran 81.0% in the latest quarter. — as of 11 September 2026.
What is Shukra Pharmaceuticals Ltd's market cap?
Shukra Pharmaceuticals Ltd's market capitalisation is ₹2,378 Cr at a share price of ₹53.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Shukra Pharmaceuticals Ltd's P/E ratio?
Shukra Pharmaceuticals Ltd trades at a P/E of 70.0×, at the 72nd percentile of its own 10-year range, against a long-run median of 60.1×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Shukra Pharmaceuticals Ltd pay a dividend?
Yes — Shukra Pharmaceuticals Ltd's dividend payout was 2% of profit in FY26, and it recorded a payout in 7 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Shukra Pharmaceuticals Ltd overvalued?
On its own history, Shukra Pharmaceuticals Ltd looks expensive: its P/E of 70.0× sits at the 72nd percentile of its 10-year range (long-run median 60.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 11 September 2026.
Is Shukra Pharmaceuticals Ltd growing?
Yes — Shukra Pharmaceuticals Ltd is growing: latest-quarter revenue +380.0% year on year, profit +1,200.0%, and the margin +57.0 pp at 81.0%. The earnings engine currently reads: improving — as of 11 September 2026.
How is Shukra Pharmaceuticals Ltd performing?
Shukra Pharmaceuticals Ltd is in a confirmed uptrend, 3 weeks in. Its latest quarter's revenue rose 380.0% and profit rose 1,200.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Shukra Pharmaceuticals Ltd in?
Turning around — profit growth swung from −50.0% at the trough to +230.0% off a 5-quarter-old trough, ROCE lifting at 37.0%. The read comes from the last 12 quarters of growth (revenue growth +114.3% latest, profit growth +230.0% latest, eps growth +245.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Shukra Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 3 of stage 2), trading +49.0% versus its 200-day average and at 89% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Shukra Pharmaceuticals Ltd beating the market?
On recent form, yes — Shukra Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +20,646% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Shukra Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Shukra Pharmaceuticals Ltd. What it measures instead: the share price is ₹53.9, the price is in a confirmed uptrend 3 weeks in. Its P/E of 70.0× sits at the 72nd percentile of its own 10-year range. — as of 11 September 2026.
Who owns Shukra Pharmaceuticals Ltd?
Promoters hold 51.2% of Shukra Pharmaceuticals Ltd, foreign institutions null%, domestic institutions 0.1% and the public 48.7% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Shukra Pharmaceuticals Ltd have too much debt?
No — Shukra Pharmaceuticals Ltd's debt-to-equity is 0.06, and operating profit covers the interest bill 29×. FY26 borrowings were ₹5.0 Cr against equity of ₹90.0 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Shukra Pharmaceuticals Ltd's capex?
Shukra Pharmaceuticals Ltd spent ₹20.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹16.0 Cr, with ₹12.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Shukra Pharmaceuticals Ltd's cash flow?
Shukra Pharmaceuticals Ltd generated ₹4.0 Cr of operating cash flow in FY26 and ₹−12.0 Cr of free cash flow after ₹16.0 Cr of capital spending. Reported profit that year was ₹22.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Shukra Pharmaceuticals Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 14% of Shukra Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹4.0 Cr against reported profit of ₹22.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is Shukra Pharmaceuticals Ltd in its business cycle?
Shukra Pharmaceuticals Ltd's FY26 operating margin was 51.0%, against a 13-year band of −10.0%–51.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 81.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Shukra Pharmaceuticals Ltd story?
The sharpest disagreement: profits are rising, but only 14% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Shukra Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Shukra Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +127.3% in a year against a +90.4% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!